keyword
MENU ▼
Read by QxMD icon Read
search

ESR1 and breast

keyword
https://www.readbyqxmd.com/read/27886589/esr1-mutations-moving-towards-guiding-treatment-decision-making-in-metastatic-breast-cancer-patients
#1
REVIEW
Lindsay Angus, Nick Beije, Agnes Jager, John W M Martens, Stefan Sleijfer
Mutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with acquired endocrine resistance in patients with ER-positive metastatic breast cancer (MBC). Functional studies revealed that these ESR1 mutations lead to constitutive activity of the ER, meaning that the receptor is active in absence of its ligand estrogen, conferring resistance against several endocrine agents. While recent clinical studies reported that the occurrence of ESR1 mutations is rare in primary breast cancer tumors, these mutations are more frequently observed in metastatic tissue and circulating cell-free DNA of MBC patients pretreated with endocrine therapy...
November 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27867016/vasohibin-2-promotes-epithelial-mesenchymal-transition-in-human-breast-cancer-via-activation-of-transforming-growth-factor-%C3%AE-1-and-hypoxia-dependent-repression-of-gata-binding-factor-3
#2
Min Tu, Zhanjun Li, Xian Liu, Nan Lv, Chunhua Xi, Zipeng Lu, Jishu Wei, Guoxin Song, Jianmin Chen, Feng Guo, Kuirong Jiang, Shui Wang, Wentao Gao, Yi Miao
Vasohibin 2 (VASH2) is identified as an angiogenic factor, and has been implicated in tumor angiogenesis, proliferation and epithelial-mesenchymal transition (EMT). To investigate the EMT role of VASH2 in breast cancer, we overexpressed or knocked down expression of VASH2 in human breast cancer cell lines. We observed that VASH2 induced EMT in vitro and in vivo. The transforming growth factor β1 (TGFβ1) pathway was activated by VASH2, and expression of a dominant negative TGFβ type II receptor could block VASH2-mediated EMT...
November 17, 2016: Cancer Letters
https://www.readbyqxmd.com/read/27848153/previous-gwas-hits-in-relation-to-young-onset-breast-cancer
#3
Min Shi, Katie M O'Brien, Dale P Sandler, Jack A Taylor, Dmitri V Zaykin, Clarice R Weinberg
PURPOSE: Genome-wide association studies (GWAS) have identified dozens of single-nucleotide polymorphisms (SNPs) associated with breast cancer. Few studies focused on young-onset breast cancer, which exhibits etiologic and tumor-type differences from older-onset disease. Possible confounding by prenatal effects of the maternal genome has also not been considered. METHODS: Using a family-based design for breast cancer before age 50, we assessed the relationship between breast cancer and 77 GWAS-identified breast cancer risk SNPs...
November 15, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27825388/impact-of-cyp19a1-and-esr1-variants-on-early-onset-side-effects-during-combined-endocrine-therapy-in-the-text-trial
#4
Harriet Johansson, Kathryn P Gray, Olivia Pagani, Meredith M Regan, Giuseppe Viale, Valentina Aristarco, Debora Macis, Antonella Puccio, Susanne Roux, Rudolf Maibach, Marco Colleoni, Manuela Rabaglio, Karen N Price, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Roswitha Kammler, Bernardo Bonanni, Barbara A Walley
BACKGROUND: Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have been associated with breast cancer risk, endocrine therapy response and side effects, mainly in postmenopausal women with early breast cancer. This analysis aimed to assess the association of selected germline CYP19A1 and ESR1 SNPs with early-onset hot flashes, sweating and musculoskeletal symptoms in premenopausal patients enrolled in the Tamoxifen and Exemestane Trial (TEXT)...
November 8, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27801670/kinetics-prognostic-and-predictive-values-of-esr1-circulating-mutations-in-metastatic-breast-cancer-patients-progressing-on-aromatase-inhibitor
#5
Florian Clatot, Anne Perdrix, Laetitia Augusto, Ludivine Beaussire, Julien Delacour, Céline Calbrix, David Sefrioui, Pierre-Julien Viailly, Michael Bubenheim, Cristian Moldovan, Cristina Alexandru, Isabelle Tennevet, Olivier Rigal, Cécile Guillemet, Marianne Leheurteur, Sophie Gouérant, Camille Petrau, Jean-Christophe Théry, Jean-Michel Picquenot, Corinne Veyret, Thierry Frébourg, Fabrice Jardin, Nasrin Sarafan-Vasseur, Frédéric Di Fiore
PURPOSE: To assess the prognostic and predictive value of circulating ESR1 mutation and its kinetics before and after progression on aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: ESR1 circulating D538G and Y537S/N/C mutations were retrospectively analyzed by digital droplet PCR after first-line AI failure in patients treated consecutively from 2010 to 2012 for hormone receptor-positive metastatic breast cancer. Progression-free survival (PFS) and overall survival (OS) were analyzed according to circulating mutational status and subsequent lines of treatment...
October 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27765917/somatic-alterations-of-targetable-oncogenes-are-frequently-observed-in-brca1-2-mutation-negative-male-breast-cancers
#6
Piera Rizzolo, Anna Sara Navazio, Valentina Silvestri, Virginia Valentini, Veronica Zelli, Ines Zanna, Giovanna Masala, Simonetta Bianchi, Marco Scarnò, Stefania Tommasi, Domenico Palli, Laura Ottini
Male breast cancer (MBC) is a rare disease. Due to its rarity, MBC research and clinical approach are mostly based upon data derived from its largely known female counterpart. We aimed at investigating whether MBC cases harbor somatic alterations of genes known as prognostic biomarkers and molecular therapeutic targets in female breast cancer.We examined 103 MBC cases, all characterized for germ-line BRCA1/2 mutations, for somatic alterations in PIK3CA, EGFR, ESR1 and CCND1 genes.Pathogenic mutations of PIK3CA were detected in 2% of MBCs...
September 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27765908/erps294-is-a-biomarker-of-ligand-or-mutational-er%C3%AE-activation-and-a-breast-cancer-target-for-cdk2-inhibition
#7
Gary K Scott, David Chu, Ravneet Kaur, Julia Malato, Daniel E Rothschild, Katya Frazier, Serenella Eppenberger-Castori, Byron Hann, Ben Ho Park, Christopher C Benz
ERα phosphorylation at hinge site S294 (pS294) was recently shown to be essential for ER-dependent gene transcription and mediated by an unknown cyclin-dependent kinase (CDK). This study was undertaken to identify the exact CDK pathway mediating pS294 formation, and to determine if this phosphorylation event occurs with, and can be targeted to treat, the ligand-independent growth of breast cancers expressing endocrine-refractory ESR1 mutations. Using a newly developed anti-pS294 monoclonal antibody, a combination of CDK specific siRNA knockdown studies and a broad panel of CDK selective inhibitors against ligand (E2)-stimulated MCF7 cells, we first identified CDK2 as the primary mediator of pS294 formation and showed that CDK2-selective inhibitors like Dinaciclib, but not CDK4/6 inhibitors like Palbociclib, can selectively prevent pS294 formation and repress ER-dependent gene expression...
October 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27761212/are-estrogen-receptor-genomic-aberrations-predictive-of-hormone-therapy-response-in-breast-cancer
#8
Sanaz Tabarestani, Marzieh Motallebi, Mohammad Esmaeil Akbari
CONTEXT: Breast cancer is the most common cancer in women worldwide. Estrogen receptor (ER) positive breast cancer constitutes the majority of these cancers. Hormone therapy has significantly improved clinical outcomes for early- and late-stage hormone receptor positive breast cancer. Although most patients with early stage breast cancer are treated with curative intent, approximately 20% - 30% of patients eventually experience a recurrence. During the last two decades, there have been tremendous efforts to understand the biological mechanisms of hormone therapy resistance, with the ultimate goal of implementing new therapeutic strategies to improve the current treatments for ER positive breast cancer...
August 2016: Iranian Journal of Cancer Prevention
https://www.readbyqxmd.com/read/27760227/reproducibility-of-digital-pcr-assays-for-circulating-tumor-dna-analysis-in-advanced-breast-cancer
#9
Sarah Hrebien, Ben O'Leary, Matthew Beaney, Gaia Schiavon, Charlotte Fribbens, Amarjit Bhambra, Richard Johnson, Isaac Garcia-Murillas, Nicholas Turner
Circulating tumor DNA (ctDNA) analysis has the potential to allow non-invasive analysis of tumor mutations in advanced cancer. In this study we assessed the reproducibility of digital PCR (dPCR) assays of circulating tumor DNA in a cohort of patients with advanced breast cancer and assessed delayed plasma processing using cell free DNA preservative tubes. We recruited a cohort of 96 paired samples from 71 women with advanced breast cancer who had paired blood samples processed either immediately or delayed in preservative tubes with processing 48-72 hours after collection...
2016: PloS One
https://www.readbyqxmd.com/read/27758888/genetic-polymorphisms-in-the-long-noncoding-rna-mir2052hg-offer-a-pharmacogenomic-basis-for-the-response-of-breast-cancer-patients-to-aromatase-inhibitor-therapy
#10
James N Ingle, Fang Xie, Matthew J Ellis, Paul E Goss, Lois E Shepherd, Judith-Anne W Chapman, Bingshu E Chen, Michiaki Kubo, Yoichi Furukawa, Yukihide Momozawa, Vered Stearns, Kathleen I Pritchard, Poulami Barman, Erin E Carlson, Matthew P Goetz, Richard M Weinshilboum, Krishna R Kalari, Liewei Wang
Genetic risks in breast cancer remain only partly understood. Here, we report the results of a genome-wide association study of germline DNA from 4,658 women, including 252 women experiencing a breast cancer recurrence, who were entered on the MA.27 adjuvant trial comparing the aromatase inhibitors (AI) anastrozole and exemestane. Single-nucleotide polymorphisms (SNP) of top significance were identified in the gene encoding MIR2052HG, a long noncoding RNA of unknown function. Heterozygous or homozygous individuals for variant alleles exhibited a ∼40% or ∼63% decrease, respectively, in the hazard of breast cancer recurrence relative to homozygous wild-type individuals...
December 1, 2016: Cancer Research
https://www.readbyqxmd.com/read/27756582/multimodal-assessment-of-estrogen-receptor-mrna-profiles-to-quantify-estrogen-pathway-activity-in-breast-tumors
#11
Anita Muthukaruppan, Annette Lasham, Kathryn J Woad, Michael A Black, Cherie Blenkiron, Lance D Miller, Gavin Harris, Nicole McCarthy, Michael P Findlay, Andrew N Shelling, Cristin G Print
BACKGROUND: Molecular markers have transformed our understanding of the heterogeneity of breast cancer and have allowed the identification of genomic profiles of estrogen receptor (ER)-α signaling. However, our understanding of the transcriptional profiles of ER signaling remains inadequate. Therefore, we sought to identify the genomic indicators of ER pathway activity that could supplement traditional immunohistochemical (IHC) assessments of ER status to better understand ER signaling in the breast tumors of individual patients...
September 13, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27748765/genomic-modelling-of-the-esr1-y537s-mutation-for-evaluating-function-and-new-therapeutic-approaches-for-metastatic-breast-cancer
#12
A Harrod, J Fulton, V T M Nguyen, M Periyasamy, L Ramos-Garcia, C-F Lai, G Metodieva, A de Giorgio, R L Williams, D B Santos, P J Gomez, M-L Lin, M V Metodiev, J Stebbing, L Castellano, L Magnani, R C Coombes, L Buluwela, S Ali
Drugs that inhibit estrogen receptor-α (ER) activity have been highly successful in treating and reducing breast cancer progression in ER-positive disease. However, resistance to these therapies presents a major clinical problem. Recent genetic studies have shown that mutations in the ER gene are found in >20% of tumours that progress on endocrine therapies. Remarkably, the great majority of these mutations localize to just a few amino acids within or near the critical helix 12 region of the ER hormone binding domain, where they are likely to be single allele mutations...
October 17, 2016: Oncogene
https://www.readbyqxmd.com/read/27730527/erratum-to-genetic-variants-of-esr1-and-sgsm3-are-associated-with-the-susceptibility-of-breast-cancer-in-the-chinese-population
#13
Tan Tan, Kai Zhang, Wenjun Chen
No abstract text is available yet for this article.
October 11, 2016: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/27717337/polymorphisms-in-the-estrogen-receptor-alpha-gene-esr1-daily-cycling-estrogen-and-mammographic-density-phenotypes
#14
F N Fjeldheim, H Frydenberg, V G Flote, A McTiernan, A-S Furberg, P T Ellison, E S Barrett, T Wilsgaard, G Jasienska, G Ursin, E A Wist, I Thune
BACKGROUND: Single nucleotide polymorphisms (SNPs) involved in the estrogen pathway and SNPs in the estrogen receptor alpha gene (ESR1 6q25) have been linked to breast cancer development, and mammographic density is an established breast cancer risk factor. Whether there is an association between daily estradiol levels, SNPs in ESR1 and premenopausal mammographic density phenotypes is unknown. METHODS: We assessed estradiol in daily saliva samples throughout an entire menstrual cycle in 202 healthy premenopausal women in the Norwegian Energy Balance and Breast Cancer Aspects I study...
October 7, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27706044/detection-and-characterization-of-circulating-tumor-associated-cells-in-metastatic-breast-cancer
#15
Zhaomei Mu, Naoual Benali-Furet, Georges Uzan, Anaëlle Znaty, Zhong Ye, Carmela Paolillo, Chun Wang, Laura Austin, Giovanna Rossi, Paolo Fortina, Hushan Yang, Massimo Cristofanilli
The availability of blood-based diagnostic testing using a non-invasive technique holds promise for real-time monitoring of disease progression and treatment selection. Circulating tumor cells (CTCs) have been used as a prognostic biomarker for the metastatic breast cancer (MBC). The molecular characterization of CTCs is fundamental to the phenotypic identification of malignant cells and description of the relevant genetic alterations that may change according to disease progression and therapy resistance. However, the molecular characterization of CTCs remains a challenge because of the rarity and heterogeneity of CTCs and technological difficulties in the enrichment, isolation and molecular characterization of CTCs...
September 30, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27684533/rna-sequencing-to-predict-response-to-neoadjuvant-anti-her2-therapy-a-secondary-analysis-of-the-neoaltto-randomized-clinical-trial
#16
Debora Fumagalli, David Venet, Michail Ignatiadis, Hatem A Azim, Marion Maetens, Françoise Rothé, Roberto Salgado, Ian Bradbury, Lajos Pusztai, Nadia Harbeck, Henry Gomez, Tsai-Wang Chang, Maria Antonia Coccia-Portugal, Serena Di Cosimo, Evandro de Azambuja, Lorena de la Peña, Paolo Nuciforo, Jan C Brase, Jens Huober, José Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou
Importance: In neoadjuvant trials, treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancers with dual HER2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targeted agent alone. Amplification and/or overexpression of HER2 currently remains the only biomarker for therapeutic decisions, but it is insufficient to explain the heterogeneous response to anti-HER2 agents. Objective: To investigate the ability of clinically and biologically relevant genes and gene signatures (GSs) measured by RNA sequencing to predict the efficacy of anti-HER2 agents...
September 29, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27672107/somatic-mutation-copy-number-and-transcriptomic-profiles-of-primary-and-matched-metastatic-estrogen-receptor-positive-breast-cancers
#17
D Fumagalli, T R Wilson, R Salgado, X Lu, J Yu, C O'Brien, K Walter, L Y Huw, C Criscitiello, I Laios, V Jose, D N Brown, F Rothé, M Maetens, D Zardavas, P Savas, D Larsimont, M J Piccart-Gebhart, S Michiels, M R Lackner, C Sotiriou, S Loi
BACKGROUND: Estrogen receptor-positive (ER+) breast cancers (BCs) constitute the most frequent BC subtype. The molecular landscape of ER+ relapsed disease is not well characterized. In this study, we aimed to describe the genomic evolution between primary (P) and matched metastatic (M) ER+ BCs after failure of adjuvant therapy. MATERIALS AND METHODS: A total of 182 ER+ metastatic BC patients with long-term follow-up were identified from a single institution. P tumor tissue was available for all patients, with 88 having matched M material...
October 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27649560/hormone-receptor-expression-analyses-in-neoplastic-and-non-neoplastic-canine-mammary-tissue-by-a-bead-based-multiplex-branched-dna-assay-a-gene-expression-study-in-fresh-frozen-and-formalin-fixed-paraffin-embedded-samples
#18
Annika Mohr, Florenza Lüder Ripoli, Susanne Conradine Hammer, Saskia Willenbrock, Marion Hewicker-Trautwein, Zdzisław Kiełbowicz, Hugo Murua Escobar, Ingo Nolte
Immunohistochemistry (IHC) is currently considered the method of choice for steroid hormone receptor status evaluation in human breast cancer and, therefore, it is commonly utilized for assessing canine mammary tumors. In case of low hormone receptor expression, IHC is limited and thus is complemented by molecular analyses. In the present study, a multiplex bDNA assay was evaluated as a method for hormone receptor gene expression detection in canine mammary tissues. Estrogen receptor (ESR1), progesterone receptor (PGR), prolactin receptor (PRLR) and growth hormone receptor (GHR) gene expressions were evaluated in neoplastic and non-neoplastic canine mammary tissues...
2016: PloS One
https://www.readbyqxmd.com/read/27648723/further-evidence-to-support-bimodality-of-oestrogen-receptor-expression-in-breast-cancer
#19
Abir A Muftah, Mohammed Aleskandarany, Sultan N Sonbul, Christopher C Nolan, Maria Diez Rodriguez, Carlos Caldas, Ian O Ellis, Andrew R Green, Emad A Rakha
BACKGROUND AND AIM: Although oestrogen receptor (ER)-negative breast cancers (BC) do not respond to hormone therapy, the response of ER-positive BC is reported to be variable which may suggest a dose dependent effect. This study aimed to assess the pattern of ER-expression in BC at the protein (IHC) and transcriptome (microarray-based gene expression) levels. MATERIALS AND METHODS: ER IHC expression was assessed in a large series of BC including 3649 core biopsies and 1892 cases prepared as TMA stained using specific antibodies...
September 20, 2016: Histopathology
https://www.readbyqxmd.com/read/27638747/multiple-noncoding-mutations-regulate-esr1-expression-in-breast-cancer
#20
(no author information available yet)
ESR1 expression is enhanced by noncoding somatic mutations and inherited SNVs in regulatory elements.
September 16, 2016: Cancer Discovery
keyword
keyword
110592
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"